Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

Andrew Huberman interviews Dr. Matthew Johnson about the science of psychedelics for treating mental illness. They define what qualifies as a psychedelic across serotonergic, NMDA-antagonist, and entactogen classes, then walk step-by-step through a Johns Hopkins psilocybin therapy session from screening to integration. Johnson argues the common therapeutic mechanism is a persisting change in self-representation, explains the difference between micro- and macrodosing (and his skepticism of microdosing claims), and details the real dangers including bad trips and destabilizing people with psychotic or bipolar predisposition. The conversation closes on the legal landscape, FDA breakthrough-therapy status for MDMA and psilocybin, exploratory work on traumatic brain injury with the UFC, and how philanthropy has funded the research.

• Johnson's lab now drops body-weight dose adjustment for psilocybin, having found across hundreds of volunteers that brain effects don't scale with body weight.
  00:34:06
• Hallucinogen-persisting perceptual disorder has NEVER been observed in thousands of supervised study participants, only in illicit use, suggesting other factors are at play.
  01:05:41
• Johnson claims the 'bad trip' may be the necessary gateway to transcendental mystical experiences linked to long-term positive outcomes.
  01:19:14
• Even after the best preparation, about a third of people on ~30mg psilocybin report a bad trip at some point in the session.
  01:34:29
• No credible peer-reviewed study has shown microdosing improves mood, creativity, or cognition; some show mild impairment of time perception.
  01:46:57
• Johnson warns chronic microdosing could carry serotonin-2B heart-valve risks (the mechanism behind fen-phen) that single therapeutic doses don't.
  01:54:47
• A $17 million gift, split between the Cohen Foundation and a Tim Ferriss-led collaborative, funded the Hopkins center.
  02:34:22
• Both psilocybin (two designations) and MDMA (for PTSD) hold FDA breakthrough-therapy status, with MDMA likely approved within a few years.
  02:41:37

• Psilocybin occurs in over 200 known species of mushrooms, and DMT is found in dozens of plants.
  00:08:24
• All classic psychedelics act as agonists or partial agonists at the serotonin 2A receptor despite differing chemical structures.
  00:09:29
• Ketamine and classic psychedelics may share effects via downstream increases in glutamate transmission.
  00:23:39
• Psilocybin's molecular structure looks similar to serotonin, while mescaline looks more like dopamine.
  00:32:33
• Aldous Huxley took 500mg of mescaline, a heroic dose, for his Doors of Perception experience.
  00:49:18
• The 'bath salts' face-eating case in Florida actually showed only cannabis in the attacker's system, an example of drug-class scapegoating.
  01:08:16
• Johnson compares psychedelics to bodybuilding and contortionism: extreme subcultures whose practices (weight training, yoga) eventually mainstream.
  01:25:04
• Alia Crum's research shows belief alone changes insulin response to identical milkshakes and weight loss from identical exercise.
  01:51:06
• Rodent work from labs like David Olson and Brian Roth shows psychedelics trigger dendrite growth and new neural connections.
  02:22:44
• People seeking trials should go to Hopkinspsychedelic.org or search Clinicaltrials.gov, not email researchers directly.
  02:45:45

Books, products and media the guest or host genuinely endorsed here — with the buy link.

Affiliate link — we may earn a commission at no extra cost to you.